1,786
Views
4
CrossRef citations to date
0
Altmetric
Author’s View

“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy

ORCID Icon &
Article: 1968611 | Received 05 Aug 2021, Accepted 11 Aug 2021, Published online: 07 Sep 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now

Articles from other publishers (3)

Carl A. Shirley, Gagan Chhabra, Deeba Amiri, Hao Chang & Nihal Ahmad. (2024) Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy. Frontiers in Immunology 15.
Crossref
Tianyun Qiao, Jinbo Zhao, Xiangbing Xin, Yanlu Xiong, Wenwen Guo, Fancheng Meng, Hui Li, Yangbo Feng, Hui Xu, Changhong Shi & Yong Han. (2022) Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model. Cancer Immunology, Immunotherapy 72:5, pages 1169-1181.
Crossref
Mengsi Zhan, Yunqi Guo, Mingwu Shen & Xiangyang Shi. (2022) Nanomaterial‐Boosted Tumor Immunotherapy Through Natural Killer Cells. Advanced NanoBiomed Research 2:12.
Crossref